Incidentalomas, defined as incidental findings on imaging, are a growing concern. Our aim was to determine the impact and outcomes of extrahepatic incidentalomas on liver transplantation.
Methods
Patients at a large liver transplant center, who had an initial MRI for hepatocellular carcinoma screening between January 2004 and March 2020 were identified. Clinical data were collected retrospectively. Survival analysis, utilizing Kaplan Meier estimates and Cox proportional hazards regression analysis, was utilized to determine factors associated with liver transplantation.
Results
720 patients were included. NASH (24.9%), HCV (22.1%) and alcohol (20.6%) were the most common causes of cirrhosis. 79.7% of patients had an extrahepatic incidentaloma. Older age and having received a liver transplant by the end of the study were associated with an incidentaloma. MELD was not associated with the presence of an incidentaloma. On univariate Cox proportional hazards regression, male sex, history of moderate alcohol use, smoking history, MELD, and incidentalomas were predictors of liver transplantation. On multivariate analysis, only MELD and the presence of an incidentaloma were found to be significant. Discovery of an incidentaloma was associated with a 30% increase in the risk of liver transplantation. Median time to transplantation did not differ based on the presence on an incidentaloma. Patients with cirrhosis from alcohol or HCV had a significantly shorter median time to transplantation than those with NASH. Renal and pancreatic lesions comprised 91% of all incidentalomas.
Conclusions
In this single-center retrospective study, extrahepatic incidentalomas were common in patients with cirrhosis. The finding of an incidentaloma was associated with a higher risk of liver transplantation despite a similar median time to transplantation if no incidentaloma was discovered.
Hinweise
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
MRI
Magnetic resonance imaging
NASH
Non-alcoholic steatohepatitis
HCV
Hepatitis C virus
MELD
Model for end-stage liver disease
CT
Computed tomography
HCC
Hepatocellular carcinoma
TUS
Transabdominal ultrasound
AASLD
American association for the study of liver diseases
BMI
Body mass index
TIPS
Transjugular intrahepatic portosystemic shunt
NIAAA
National Institute on alcohol abuse and alcoholism
INR
International normalized ratio
IPMN
Intraductal papillary mucinous neoplasms
EUS
Endoscopic ultrasound
RCC
Renal cell carcinoma
PDAC
Pancreatic ductal adenocarcinoma
NET
Neuroendocrine tumor
IARs
Individuals at high risk
HNSCC
Head and neck squamous cell cancer
Background
The widespread use of abdominal imaging has led to an increased detection of incidental findings, termed incidentalomas, which are defined as incidental radiographic findings that were unexpected or unrelated to the study’s initial purpose [1, 2]. The frequency of incidentalomas varies depending on the imaging study, with the highest detection rates occurring in computed tomography (CT) of the chest (45%), CT enterography (38%), and magnetic resonance imaging (MRI) of the heart (34%) [3]. The most common types of incidentalomas are pituitary [1 in 10], thyroid (up to 50%), pulmonary (8 to 51%), hepatic (15%), pancreatic (2%), adrenal (3 to 4%) and renal (up to 33% in older adults) [4].
Patients with cirrhosis undergo screening for hepatocellular carcinoma (HCC) with transabdominal ultrasound (TUS) as the preferred imaging modality. [5] Obesity, abnormal liver texture, steatosis, technologist’s experience and technical restrictions limit the use of TUS for detecting HCC [6]. The sensitivity for detecting HCC with TUS is 63% for early lesions [7]. In contrast, MRI has a sensitivity of 84.8% for lesions smaller than 2 cm as opposed to 27.3% for TUS [8]. Although, MRI has higher sensitivity, current guidelines by the American Association for the Study of Liver Diseases (AASLD) recommend TUS for HCC surveillance [5, 8]. However, given the limitations of TUS, a growing number of liver transplant centers use MRI as the preferred method for screening [9‐11].
Anzeige
Cirrhosis leads to the development of extrahepatic manifestations, including benign and malignant conditions [12, 13]. Benign extrahepatic abnormalities include splenomegaly, ascites, portal hypertension, varices, and bowel and gallbladder edema [13]. The frequency of malignant conditions is increased in patients with cirrhosis compared to the general population and include colorectal and lung cancers (fourfold increase), pancreatic cancer (fivefold), esophageal cancer (eightfold), cholangiocarcinoma (13-fold), and HCC (26-fold) [12]. Given the increased risk of developing extrahepatic abnormalities, the presence of cirrhosis may lead to a higher frequency of benign and malignant incidentalomas.
The significance of incidentalomas in patients with cirrhosis is unclear. With the increasing use of MRI for the screening of HCC, the frequency of incidentalomas may be expected to increase as well. Therefore, we aimed to determine the frequency and outcomes of extrahepatic incidetalomas in patients with cirrhosis undergoing MRI for HCC screening. We also aimed to determine factors that may be associated with extrahepatic incidentalomas, and the impact of incidentalomas on liver transplantation.
Methods
Study design and patient selection
The study was approved by the Institutional Review Board. Individual consent for the study was waived. This retrospective study was performed at a large tertiary referral center for liver transplantation and included patients with cirrhosis who underwent MRI as the initial study for HCC screening between January 2004 and March 2020. Patients were excluded if they were younger than 18 years, lacked evidence of cirrhosis, or underwent an initial screening study other than MRI. All information was collected retrospectively, stored in a secure database, and deidentified.
Data collection
Demographic data included age at time of initial MRI, sex, race, ethnicity, body mass index (BMI), smoking history, moderate alcohol use, prior history of transjugular intrahepatic portosystemic shunt (TIPS), etiology of liver cirrhosis, and liver transplantation status at the end of the study period. Moderate alcohol use was defined per the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria of > 14 drinks per week for a male and > 7 drinks per week for a female [14]. Radiographic variables included whether an extrahepatic incidentaloma was discovered, the type of incidental lesion, its size, and whether it was solid or cystic. The radiographic data were obtained through retrospective review of the imaging reports of the MRIs. An extrahepatic incidentaloma was defined as any radiographic finding (such as renal cysts, pancreatic cysts, adrenal adenomas, solid lesions, etc.) that was unexpected or unrelated to the study’s initial purpose. Laboratory data included sodium, total bilirubin, creatinine, international normalized ratio (INR), and model for end-stage liver disease (MELD) at the time of the initial MRI. Pathology data were obtained for patients who underwent biopsy or resection of the incidentaloma. Clinical data regarding the incidentalomas were collected, and included the management approach (observation, surgery), and whether further consultation was pursued.
Anzeige
Data and statistical analysis
Descriptive statistics for continuous variables were reported as means, and standard deviations. Categorical variables were summarized with number and percentage of patients. Comparisons between patients with and without incidentalomas, and if liver transplantation occurred by the end of the study period, were performed using Student’s t-test, Pearson’s chi-squared test, or Fisher’s exact test as indicated in the accompanying tables.
Survival analysis methods were employed with the time of the initial MRI being defined as time zero. The primary event was defined as the liver transplantation, and time to liver transplantation was recorded for all patients who underwent transplantation during the study period. The secondary event was defined as the discovery of an extrahepatic incidentaloma, and time to incidentaloma discovery was recorded for all patients who had an extrahepatic incidentaloma discovered. Patients were censored at either (1) time of liver transplantation, (2) time at last follow up appointment during the study period, or (3) time of death prior to liver transplantation.
Kaplan Meier curves were constructed for the primary event and comparisons were performed based on (1) the three most common causes of cirrhosis in our cohort, and (2) whether an extrahepatic incidentaloma was discovered. Median time to liver transplantation with 95% confidence intervals (95% CI) were reported. Univariate Cox proportional hazards regression analysis was performed to determine predictors of the primary event of liver transplantation. Variables that were significant at an alpha level of 0.05 were inputted into a multivariate Cox proportional hazards model to adjust for potential confounders. The discovery of an incidentaloma was treated as a time dependent variable and adjusted accordingly based on the time to incidentaloma discovery.
All patients in this cohort had complete data for analysis. All tests were two-sided with an alpha level set at 0.05 for statistical significance. The statistical analysis was performed utilizing BlueSky Statistics software v. 7.10 (BlueSky Statistics LLC, Chicago, IL, USA).
Results
Patients characteristics
A total of 720 patients were included in this study. Baseline characteristics of all patients are summarized in Table 1. The three main etiologies of cirrhosis were non-alcoholic steatohepatitis (NASH) (24.9%), hepatitis C (22.1%), and alcohol (20.6%), which together represented 67.6% of all patients. The cohort had 450 males (62.5%), and most patients were White (88.3%). The mean age was 57.7 years (standard deviation [SD] 12.1), mean MELD 14.4 (SD 6.9), and mean BMI 29.4 (SD 6.3). By the end of the study period, a total of 532 patients (73.9%) had undergone liver transplantation, and 574 patients (79.7%) had an extrahepatic incidentaloma discovered.
Table 1
Baseline Characteristics of All Patients
Variables
N = 720
Age, year (mean, SD)
57.7 (12.1)
Male Sex, %
450 (62.5%)
BMI, kg/m2, (mean, SD)
29.4 (6.3)
Obesity, %
285 (39.6%)
White, %
636 (88.3%)
African American, %
32 (4.4%)
Asian, %
17 (2.4%)
Other Race, %
35 (4.9%)
Hispanic/Latino, %
48 (6.7%)
History of Moderate Alcohol Use, %
142 (19.7%)
Ever smoked, %
399 (55.4%)
Current smoker, %
19 (2.6%)
Sodium, mmol/L (mean, SD)
138 (4.1)
Total Bilirubin, mg/dL (mean, SD)
2.7 (4.2)
INR, (mean, SD)
1.4 (0.4)
Creatinine, mg/dL (mean, SD)
1.0 (0.5)
MELD, (mean, SD)
14.4 (6.9)
MELD ≥ 18, %
201 (27.9%)
MELD ≥ 26, %
49 (6.8%)
Etiology of Cirrhosis
A1AT Deficiency, %
17 (2.4%)
Alcohol, %
148 (20.6%)
Autoimmune, %
45 (6.3%)
Cryptogenic, %
49 (6.81%)
Hemochromatosis, %
9 (1.3%)
Hepatitis B, %
18 (2.5%)
Hepatitis C, %
159 (22.1%)
NASH, %
179 (24.9%)
Other, %
16 (2.2%)
Primary Biliary Cirrhosis, %
32 (4.4%)
Primary Sclerosing Cholangitis, %
45 (6.3%)
Wilson’s Disease, %
3 (0.4%)
History of prior TIPS
38 (5.3%)
Incidentaloma Discovered
574 (79.7%)
Transplanted at End of Study
532 (73.9%)
SD standard deviation, BMI body mass index, INR international standardized ratio, MELD model for end-stage liver disease, A1AT alpha-1 antitrypsin, NASH non-alcoholic steatohepatitis TIPS transjugular intrahepatic portosystemic shunt
Comparisons of baseline characteristics are summarized in Table 2 according to whether an extrahepatic incidentaloma was discovered, and in Table 3 according to whether liver transplantation was performed by the end of the study period. Older age, lower total bilirubin, and having been transplanted by the end of the study period were associated with the discovery of an incidentaloma, (p < 0.05). Notably, neither the MELD score nor the etiology of cirrhosis was associated with the discovery of an incidentaloma. Multiple variables were associated with liver transplantation, including being a male, having ever smoked, lower serum sodium, higher total bilirubin, creatinine, INR, and MELD, having alcohol or hepatitis C as the etiology of liver cirrhosis, and having had an extrahepatic incidentaloma discovered during the study period.
Table 2
Baseline characteristics according to if incidentaloma was discovered on MRI surveillance for HCC
Incidentaloma Absent N = 146
Incidentaloma Discovered N = 574
p value
Age, year (mean, SD)
50.5 (15.5)
59.6 (10.2)
< 0.0011
Male Sex, %
85 (58.2%)
365 (63.6%)
0.2312
BMI, kg/m2, (mean, SD)
28.6 (6.6)
29.6 (6.2)
0.08481
Obesity, %
56 (38.4%
229 (39.9%)
0.7342
White, %
126 (86.3%)
510 (88.9%)
0.3922
African American, %
7 (4.8%)
25 (4.4%)
0.8223
Asian, %
4 (2.7%)
13 (2.3%)
0.7603
Other Race, %
9 (6.2%)
26 (4.5%)
0.3933
Hispanic/Latino, %
10 (6.8%)
38 (6.6%)
0.8553
History of Moderate Alcohol Use, %
25 (17.1%)
117 (20.4%)
0.3772
Ever smoked, %
73 (50.0%)
326 (56.8%)
0.1402
Current smoker, %
6 (4.1%)
13 (2.3%)
0.2443
Sodium, mmol/L (mean, SD)
137.5 (3.9)
138.1 (4.1)
0.14031
Total Bilirubin, mg/dL (mean, SD)
3.5 (5.4)
2.5 (3.8)
0.04471
INR, (mean, SD)
1.4 (0.5)
1.4 (0.4)
0.53121
Creatinine, mg/dL (mean, SD)
1.0 (0.6)
1.0 (0.5)
0.67001
MELD, (mean, SD)
15.1 (7.2)
14.2 (6.9)
0.17641
MELD ≥ 18, %
47 (32.2%)
154 (26.8%)
0.2152
MELD ≥ 26, %
12 (8.2%)
37 (6.4%)
0.4623
Etiology of Cirrhosis
0.9312
NASH, %
31 (21.2%)
148 (25.8%)
0.2562
Hepatitis C, %
29 (19.9%)
130 (22.6%)
0.4692
Alcohol, %
28 (19.2%)
120 (20.9%)
0.6452
History of prior TIPS
7 (4.8%)
31 (5.4%)
1.0003
Transplanted at end of study
98 (67.1%)
434 (75.6%)
0.0372
P values significant at p < 0.05 are bolded in the accompanying tables
MRI magnetic resonance imaging, HCC hepatocellular carcinoma, SD standard deviation, BMI body mass index, INR international standardized ratio, MELD model for end-stage liver disease, NASH non-alcoholic steatohepatitis, TIPS transjugular intrahepatic portosystemic shunt
1Student T test, independent samples, two-sided, equal variance not assumed
2Pearson’s Chi Square Test
3Fisher’s Exact Test
Table 3
Baseline characteristics according to if liver transplantation was performed by the end of study period
Not Transplanted N = 188
Transplanted N = 532
p value
Age, year (mean, SD)
59.2 (14.5)
57.2 (11.0)
0.07901
Male Sex, %
102 (54.3%)
348 (65.4%)
0.0072
BMI, kg/m2, (mean, SD)
29.3 (6.9)
29.4 (6.0)
0.77771
Obesity, %
74 (39.4%)
211 (39.7%)
0.9422
White, %
166 (88.3%)
470 (88.3%)
0.9862
African American, %
10 (5.3%)
22 (44.1%)
0.5373
Asian, %
5 (2.7%)
12 (2.3%)
0.7813
Other Race, %
7 (3.7%)
28 (5.3%)
0.5543
Hispanic/Latino, %
8 (4.3%)
40 (7.5%)
0.1723
History of Moderate Alcohol Use, %
29 (15.4%)
113 (21.2%)
0.085
Ever smoked, %
90 (47.9%)
309 (58.1%)
0.0152
Current smoker, %
19 (10.1%)
0 (0.0%)
< 0.0013
Sodium, mmol/L (mean, SD)
139.2 (3.0)
137.5 (4.3)
< 0.0011
Total Bilirubin, mg/dL (mean, SD)
1.3 (2.4)
3.2 (4.5)
< 0.0011
INR, (mean, SD)
1.2 (0.3)
1.4 (0.5)
< 0.0011
Creatinine, mg/dL (mean, SD)
1.0 (0.4)
1.0 (0.6)
0.18341
MELD, (mean, SD)
10.4 (4.3)
15.8 (7.1)
< 0.0011
MELD ≥ 18
11 (5.9%)
190 (35.7%)
< 0.0013
MELD ≥ 26
1 (0.5%)
48 (9.0%)
< 0.0013
Etiology of Cirrhosis
0.0562
NASH, %
52 (27.7%)
127 (23.9%)
0.3022
Hepatitis C, %
31 (16.5%)
128 (24.1%)
0.0312
Alcohol, %
29 (15.4%)
119 (22.4%)
0.0412
History of prior TIPS
6 (3.2%)
32 (6.0%)
0.1833
Incidentaloma Discovered
140 (74.5%)
434 (81.6%)
0.037
P values significant at p < 0.05 are bolded in the accompanying tables
MRI magnetic resonance imaging, SD standard deviation, BMI body mass index, INR international standardized ratio, MELD model for end-stage liver disease, NASH non-alcoholic steatohepatitis, TIPS transjugular intrahepatic portosystemic shunt
1Student T test, independent samples, two-sided, equal variance not assumed
2Pearson’s Chi Square Test
3Fisher’s Exact Test
Kaplan Meier analysis
Kaplan Meier Curves are reported in Figs. 1 and 2. The median time to liver transplantation was statistically different amongst the three most common etiologies of liver cirrhosis, p = 0.00831. Patients with alcohol or hepatitis C as the cause of their cirrhosis had a significantly shorter time to liver transplantation than those with NASH. The median time to liver transplantation was 366 days (95% CI: 265–546) and 482 days (95% CI: 374–617) for patients with cirrhosis from alcohol, or hepatitis C, respectively. Patients with NASH had the longest time to liver transplantation at 948 days (95% CI: 619–1200). The median time to liver transplantation did not different according to if an extrahepatic incidentaloma was discovered during the study period, p = 0.778. The median time to liver transplantation was 494 days (95% CI: 382–813) without an incidentaloma, and 571 days (95% CI: 482–685) with an incidentaloma.
Fig. 1
Kaplan–Meier Estimates for being transplanted according to etiology of cirrhosis
Fig. 2
Kaplan–Meier estimates for being transplanted according to incidentaloma being discovered
×
×
Cox proportional hazards regression analysis
The univariate and multivariate models to determine predictors of liver transplantation are reported in Tables 4 and 5, respectively. On univariate analysis, multiple variables were found to be significant at p < 0.05, including male sex, having a history of moderate alcohol use, having ever smoked, MELD, and having alcohol as the etiology of liver cirrhosis. The discovery of an extrahepatic incidentaloma was also significantly associated with liver transplantation, HR: 1.3126 (95%: 1.0858–1.5869), p = 0.0050, on univariate analysis. These variables were inputted into a multivariate model, and were adjusted for age, BMI, White race, Hispanic/Latino ethnicity, prior history of a TIPS, and NASH cirrhosis. On multivariate analysis, only MELD and the discovery of an extrahepatic incidentaloma remained statistically significant. Every point increase in MELD was associated with a 12% increased risk of liver transplantation (95% CI: 1.1060–1.1380), p < 0.001. The discovery of an extrahepatic incidentaloma was associated with a 30% increased risk of liver transplantation (95% CI: 1.0679–1.5763), p = 0.0088.
Table 4
Univariate Cox proportional hazards regression analysis for predicting liver transplantation
HR
2.5%
97.5%
p-value
Age, per 1 year
1.0000
0.9900
1.0100
0.9172
Age [18,40) years
0.9100
0.6800
1.2200
0.5397
Age [40,50) years
0.9000
0.6900
1.1800
0.4552
Age [50,65) years
1.1500
0.9700
1.3700
0.0993
Age ≥ 65 years
0.9300
0.7700
1.1200
0.9300
Male Sex
1.2800
1.0700
1.5300
0.0075
BMI, per 1 kg/m2
0.9900
0.9800
1.0100
0.3536
Obesity
0.9500
0.8000
1.1300
0.5819
White
0.8800
0.6700
1.1400
0.3303
African American
0.8557
0.6300
1.4700
0.8557
Asian
0.9364
0.5800
1.8200
0.9364
Other Race
1.3800
0.9400
2.0200
0.0963
Hispanic/Latino
1.3600
0.9900
1.8800
0.0611
History of Moderate Alcohol Use
1.5200
1.2400
1.8800
< 0.0001
Ever smoked
1.2100
1.0200
1.4400
0.0293
Sodium, per 1 mmol/L
0.9300
0.9100
0.9500
< 0.0001
Total Bilirubin, per 1 mg/dL
1.1500
1.1300
1.1700
< 0.0001
INR, per 1 point
2.5300
2.1800
2.9400
< 0.0001
Creatinine, per 1 mg/dL point
1.3300
1.1500
1.5500
0.0001
MELD, per 1 point
1.1200
1.1100
1.1400
< 0.0001
MELD ≥ 18
2.8309
2.3151
3.4616
< 0.0001
MELD ≥ 26
2.5241
1.8162
3.5080
< 0.0001
Etiology of Cirrhosis
1.2900
1.1300
1.4600
< 0.0001
NASH
0.8300
0.6800
1.0100
0.0636
Hepatitis C
1.0700
0.8800
1.3100
0.5049
Alcohol
1.5600
1.2700
1.9100
< 0.0001
History of prior TIPS
1.1500
0.8000
1.6500
0.4422
Binary Time-Dependent Variable
Incidentaloma Discovered
1.3126
1.0858
1.5869
0.0050
P values significant at p < 0.05 are bolded in the accompanying tables
BMI body mass index, INR international standardized ratio, MELD model for end-stage liver disease, NASH non-alcoholic steatohepatitis, TIPS transjugular intrahepatic portosystemic shunt
Table 5
Multivariate Cox proportional hazards regression analysis for predicting liver transplantation
HR
2.5%
97.5%
p value
Age, per 1 year
1.0060
0.9983
1.0139
0.1277
Male Sex
1.0948
0.9095
1.3178
0.3384
BMI, per 1 kg/m2
0.9973
0.9833
1.0166
0.7110
White
0.9540
0.7241
1.2570
0.7380
Hispanic/Latino
1.3141
0.9436
1.8302
0.1060
History of Moderate Alcohol Use
1.0178
0.8052
1.2865
0.8827
Ever smoked
1.1609
0.9656
1.3956
0.1125
MELD, per 1 point
1.1219
1.1060
1.1380
< 0.001
NASH
0.9365
0.7464
1.1751
0.5712
History of prior TIPS
0.8839
0.6120
1.2766
0.5106
Binary Time-Dependent Variable
Incidentaloma Discovered
1.2975
1.0679
1.5763
0.0088
P values significant at p < 0.05 are bolded in the accompanying tables
BMI body mass index, MELD model for end-stage liver disease, NASH non-alcoholic steatohepatitis, TIPS transjugular intrahepatic portosystemic shunt
Anzeige
Extrahepatic incidentalomas
A total of 690 extrahepatic lesions were found amongst 720 patients, Table 6. Approximately 80% of patients had an incidentaloma discovered, and 106 patients (18.5%) had more than one extrahepatic incidentaloma discovered. Most of these incidental findings included renal (60.9%) and pancreatic lesions (30.1%), representing 91.0% of all incidentalomas. Most incidentalomas were managed with observation (98.8%). Amongst renal and pancreatic incidentalomas, 1.2% and 52.4% were referred to urology or gastroenterology, respectively, Table 7. Amongst all incidentalomas, only 16 underwent biopsy or resection, of which, nearly 50% were pancreatic lesions. A total of 7 malignant incidentalomas were diagnosed.
Table 6
Types of extra-hepatic incidentalomas
Patients with Incidentalomas, N = 574
Total, %
Total number of Incidentalomas
690
Patients with multiple incidentalomas
106 (18.5%)
Types of incidentalomas
Kidney
420 (60.9%)
Pancreas
208 (30.1%)
Spleen
25 (3.6%)
Adrenal
11 (1.6%)
Gallbladder
11 (1.6%)
Pelvic
9 (1.3%)
Bone
4 (0.6%)
Stomach
2 (0.3%)
Number of incidentalomas undergoing biopsy/resection
16 (2.3%)
Pancreas
7 (47.1%)
Kidney
3 (17.6%)
Gallbladder
4 (23.5%)
Pelvis
1 (5.9%)
Stomach
1 (5.9%)
Number of malignancies detected
7 (1.0%)
Gastric Neuroendocrine Tumor
1 (14.3%)
Cholangiocarcinoma
2 (28.6%)
Renal cell carcinoma
3 (42.9%)
Pancreatic adenocarcinoma
1 (14.3%)
Management of incidentalomas
Observation
682 (98.8%)
Surgery, alone
5 (0.7%)
Chemotherapy/Radiation, alone
2 (0.3%)
Surgery and Chemotherapy/Radiation
1 (0.1%)
Table 7
Features of Kidney and Pancreatic Incidentalomas
Incidentaloma, N = 690
Total, %
Kidney or Pancreatic
628 (91.0%)
Kidney
420
Type of Lesion
Simple Cyst
417 (99.3%)
Solid Lesion
3 (0.7%)
Size of Lesion
< 1 cm
396 (94.3%)
[1,3) cm
15 (3.6%)
[3, 5) cm
3 (0.7%)
≥ 5 cm
6 (1.4%)
Referred to Urology
5 (1.2%)
Pancreas
208
Type of Lesion
IPMN, Cystic Lesion
207 (99.5%)
Solid Lesion
1 (0.5%)
Size of Lesion
< 1 cm
169 (81.3%)
[1,3) cm
36 (17.3%)
[3, 5) cm
2 (1.0%)
≥ 5 cm
1 (0.5%)
Referred to Gastroenterology
109 (52.4%)
Underwent EUS
12 (5.8%)
IPMN intraductal papillary mucinous neoplasm, EUS endoscopic ultrasound
The overwhelming majority of renal incidentalomas were simple cysts (99.3%) and characterized as Bosniak 1 or 2 by the reading radiologist. The three solid renal lesions were biopsied and found to be renal cell carcinoma. Similarly, most pancreatic lesions were characterized as intraductal papillary mucinous neoplasms (IPMN) (99.5%) by the reading radiologist and were sub-centimeter (81.3%). Only 12 of all pancreatic lesions underwent endoscopic ultrasound (EUS). Table 8 summarizes the findings of EUS and the subsequent pathology. Only the solid pancreatic lesion was found to be malignant, whereas the other biopsied pancreatic lesions were confirmed to be benign.
Table 8
Features of pancreatic lesions that underwent endoscopic ultrasound
1.4 × 2.2 cm cystic lesion at pancreatic head, likely IPMN
105
Multicystic, septated, 22 × 15 mm lesion
Yes
Malignancy absent, mucinous epithelium
Multilobulated pancreatic tail cystic lesion, 2.4 × 2.9 cm
N/A
Septated lesion, 28 mm, side-branch IPMN
Yes
Malignancy absent, mucinous epithelium
Parenchymal atrophy, innumerable tiny cysts; irregular main duct
N/A
Many benign cysts in tail; largest 7 mm
No
N/A
3.3 × 2.3 cm septated cystic lesion at pancreatic neck
6
Multiloculated 2.75 × 1.98 cm cyst at neck
Yes
Malignancy absent, mucinous epithelium
Numerous unilocular cysts at head, largest 14 mm
255
12 × 10 mm cyst in pancreatic head
Yes
Malignancy absent, mucinous epithelium
1.7 cm hypoenhancing head mass
103
1.7 cm pancreatic head mass
Yes
Adenocarcinoma
3 mm cystic lesion at uncinate process
N/A
8 × 8 mm uncinate cystic lesion
No
N/A
Few sub-5 cm cystic foci in pancreas
44
Few cysts in the pancreatic head
No
N/A
7–8 mm enhancing lesion at uncinate process, suspicious for NET
35
Multiple cystic lesions at uncinate, 10 × 10 mm
Yes
Malignancy absent, mucinous epithelium
Small cystic lesions, likely side-branch IPMNs
29
Pancreatic head cysts, 3 × 3 mm, no mass
No
N/A
Small cystic lesions, largest is 8 × 12 mm, likely IPMN
N/A
25 × 17 mm pancreatic head cystic lesion
Yes
Malignancy absent, mucinous epithelium
MRI magnetic resonance imaging; CA 19–9, carbohydrate antigen 19–9 (reference range: < 55 U/mL); EUS endoscopic ultrasound, N/A not available, NET neuroendocrine tumor, IPMN intraductal papillary mucinous neoplasm
A total of 7 cancers were diagnosed (1.0% of all incidentalomas). Table 9 summarizes the features of the malignant incidentalomas. The malignant lesions include three renal cell carcinomas (RCC) (42.9%), two cholangiocarcinomas (28.6%), one pancreatic adenocarcinoma (PDAC), and one gastric neuroendocrine tumor (NET). None of the patients had metastases. Four out of seven patients eventually underwent liver transplantation. One patient underwent neoadjuvant chemotherapy for cholangiocarcinoma before having liver transplantation for curative intent. Only one patient died from a malignant incidentaloma.
Table 9
Features of malignant incidentalomas
Incidental Finding
Size
Pathology
Treatment
Transplanted
Gastric solid lesion
< 1 cm
Well-differentiated NET
EMR, Cured
No
Gallbladder solid lesion
1–3 cm
Cholangiocarcinoma
Chemoradiation, Died
No
Renal solid lesion
> 5 cm
Renal cell carcinoma, clear cell
Nephrectomy, Cured
Yes
Gallbladder solid lesion
1–3 cm
Cholangiocarcinoma
Neoadjuvant Chemotherapy, Cured with transplantation
Yes
Renal solid lesion
1–3 cm
Renal cell carcinoma, papillary
Nephrectomy, Cured
Yes
Renal solid lesion
< 1 cm
Renal cell carcinoma, clear cell
Nephrectomy, Cured
Yes
Pancreatic solid lesion
1–3 cm
Pancreatic adenocarcinoma
Chemotherapy and Surgery, Cured
No
NET neuroendocrine tumor, EMR endoscopic mucosal resection
Discussion
The main findings of our study were: (1) neither MELD nor the etiology of cirrhosis were associated with extrahepatic incidentalomas, (2) only MELD and the discovery of an incidentaloma were predictors of liver transplantation after adjusting for potential confounders, (3) the discovery of an incidentaloma did not affect the median time to liver transplantation, and (4) the discovery of a malignant incidentaloma was rare but led to cures in all but one patient.
Anzeige
Few studies have studied the frequency and outcomes of incidentalomas discovered on screening MRI. Ibrahim et al., reported the frequency of incidentalomas on MRI was assessed in individuals at high risk (IARs) for PDAC [15]. A total of 459 incidentalomas were discovered, eleven of which were cancerous (1.9%) and six metastatic at diagnosis. The early detection of cancer was beneficial in five of eleven IARs. In another study, whole-body MRI was performed to detect the frequency of incidentalomas in 118 healthy volunteers (mean age 47.4 years, range 20–81) [16]. Seventy percent of volunteers had an incidental finding detected, and a total of 103 benign lesions were found. Only 2 malignant lesions (1.9%) were found. In contrast to others, our study is the first to determine the frequency, and clinical outcomes of extrahepatic incidentalomas in patients with cirrhosis undergoing MRI for the screening of HCC. Like prior studies, we found that incidental malignancies were rare, and that their detection led to cure in most patients.
To our knowledge, our study is the only one to have explored the association between extrahepatic incidentalomas and liver transplantation. It remains unclear why the discovery of an incidentaloma was found to be a significant predictor of liver transplantation. Incidental findings on imaging have been reported to lead to a “cascade effect”, whereby the incidentaloma leads to further testing by providers [17, 18]. In a national survey of U.S. physicians, 99.4% of respondents reported having experienced “cascades of care” whereby incidental findings led respondents to perform additional testing [19]. In a retrospective study of 592 patients with head and neck squamous cell cancer (HNSCC) who underwent staging with PET/CT, incidental findings occurred in 61.5% of patients. The discovery of an incidental finding was a significant predictor of treatment delay in this cohort [20]. Liver transplantation requires an extensive evaluation of the recipient’s comorbidities and contraindications to transplantation, which include extrahepatic malignancy [21]. Although non-significant, patients with incidentalomas appeared to have a longer time to liver transplantation than those without incidentalomas, indicating a possible treatment delay due to more extensive evaluation as seen in the study of patients with HNSCC.
Although current guidelines by the AASLD recommend TUS over MRI for HCC screening, the former has multiple limitations, that may lead to failure to detect early-stage cancer when it is the most curable [22]. Studies suggest MRI has a higher sensitivity for detecting early-stage HCC and may be more cost-effective in certain populations [5, 8‐11, 23]. Curing HCC becomes increasingly difficult when the size of the HCC becomes greater than 2–2.5 cm [24‐26]. TUS has a sensitivity between 27.3 and 63% for detecting early-stage lesions that are less than 2 cm [7, 8]. Additionally, abnormal liver parenchyma, obesity, ascites or hepatic steatosis may further decrease the sensitivity for the detection of HCC by attenuating ultrasound waves [22]. By 2030, 51% of the United states population will be obese [27]. With the increasing incidence of obesity, NASH and steatosis are likely to increase as well, further limiting the utility of TUS. Therefore, the use of MRI for screening of HCC will likely increase in the future, leading to a higher number of extrahepatic incidentalomas.
Our study has several limitations. First, the retrospective nature of the study limited our ability to determine the thought process behind the management of extrahepatic incidentalomas, which may have led to potential confounders. These potential confounders could have contributed to the “cascade effect” leading to higher rates of liver transplantation in those with incidentalomas. Second, most patients in our cohort were White, therefore, our findings on the benign nature of extrahepatic incidentalomas may not be generalizable to other racial backgrounds, who have a higher incidence of certain cancers, such as lung, prostate and colorectal malignancies in African Americans [28]. Third, we were unable to measure, and adjust for the potential confounding of MRI sensitivity over time. Over the long course of this study, the MRI scanners in our institution have been upgraded and replaced several times, and it is likely that increases in magnet field strength and improved imaging software application that were used in our most recent scans allow for better detection of smaller extrahepatic incidentalomas. Fourth, the average MELD score of our patient population was relatively low and may not be generalizable to other liver transplant programs across the country. Fifth, the presence of incidentalomas was determined through retrospective review of the imaging report, and not by manual re-read of every scan. This approach was felt to be sufficient given imaging reports are the standard means by which imaging findings are communicated in clinical practice. Finally, although our study identified a large proportion of patients with cirrhosis who underwent MRI for HCC surveillance at our institution, it was not exhaustive of all patients.
Anzeige
We believe our study provides insight into the impact of extrahepatic incidentalomas on liver transplantation. Given the worsening obesity epidemic, the prevalence of liver disease and HCC is expected to increase [29]. With higher failure rates for HCC detection in obese patients, TUS may not be the preferred screening modality for HCC in the coming years, leading to increased utilization of MRIs and a higher prevalence of extrahepatic incidentalomas. The increase in incidentalomas may have a “cascade effect” which could potentially lead to increases in the total number of liver transplantation, thereby, increasing the demand of a limited resource.
Conclusions
In this large retrospective study of patients with cirrhosis at a large liver transplantation program, most patients had an extrahepatic incidentaloma discovered on routine MRI for the screening of HCC. Renal and pancreatic cysts were the most common incidentalomas discovered and most were managed conservatively with observation. One percent of extrahepatic incidentalomas were cancerous. The discovery of an extrahepatic incidentaloma was associated with an increased risk of liver transplantation after adjusting for multiple covariates relevant to the cirrhosis population. Although the exact reason for this association remains unclear, the “cascade effect” may explain this observation. Further studies at other liver transplantation centers are needed to validate this finding. With the rising obesity epidemic, the use of MRI for HCC screening will likely continue to increase leading to an increased incidence in incidentalomas, and possibly, more liver transplantation.
Acknowledgements
An abstract, entitled “Incidental Extrahepatic Findings on Magnetic Resonance Imaging in Patients with Liver Cirrhosis Undergoing Surveillance for Hepatocellular Carcinoma”, was presented as a poster presentation at the annual American College of Gastroenterology conference in 2021, and subsequently published in The American Journal of Gastroenterology: October 2021–Volume 116–Issue–p S510 https://doi.org/10.14309/01.ajg.0000777848.40794.56
Declarations
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by Mayo Clinic’s Institutional Review Board Committee. Given this study is a retrospective cohort study, individual consent to participate was not required and it was waived and approved by our Institutional Review Board Committee prior to stating this study.
Consent for publication
Not applicable.
Competing interests
The authors (P.C., H.M.G., F.S., M.O., B.M., A.W.B., and W.C.P) declare that they have no conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.
Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.
Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.
Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
